Morgan Stanley Reiterates Overweight on Immunocore Hldgs, Maintains $79 Price Target
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Andrew Galler has reiterated an Overweight rating on Immunocore Hldgs (NASDAQ:IMCR) and maintained a $79 price target.
July 11, 2023 | 1:16 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Morgan Stanley has reiterated an Overweight rating on Immunocore Hldgs and maintained a $79 price target, indicating a positive outlook for the company.
The reiteration of an Overweight rating by Morgan Stanley indicates their belief in the company's potential for above-average performance. The maintained price target of $79 suggests that they believe the stock is currently undervalued, which could lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100